The addition of gefitinib, an EGFR-TKI used in clinical practice for diseases such as non-small cell lung cancer, significantly decreased the expression of CLDND1, which was increased by EGF (Figure 6B). Here, EGFR is linked to non-small cell lung carcinoma.